TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01217203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2101 combined to lenalidomide
Description: Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)
Study: NCT04242966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Protein/Amino Acid Group
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound measure
Description: Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound measure
Description: Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
Study: NCT02429401

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adapted brief motivational interview
Description: 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted brief motivational interview
Description: Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
Study: NCT03154528

Intervention type: DIAGNOSTIC_TEST
Intervention: serum vitamin D level by ELISA
Description: The study will include 60 patients with androgenetic alopecia (30 males \& 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: serum vitamin D level by ELISA
Description: The study will include 60 patients with androgenetic alopecia (30 males \& 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
Study: NCT00071409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP-Peptide
Description: 1.5 mL, once daily, self-administered SC injection for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP-Peptide
Description: 1.5 mL, once daily, self-administered SC injection for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study: NCT02182011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Study: NCT03877718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 5: Promethazine HCl 37.5 mg
Description: One capsule of promethazine HCl 37.5 mg
Study: NCT02182011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Study: NCT00802750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE
Description: LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE
Description: Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters.
Study: NCT03094520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Description: sham stimulation
Study: NCT03973437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial inteligence associated ulcerative colitis severity scoring system
Description: Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
Study: NCT03877718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One capsule of placebo
Study: NCT03973437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional human scoring
Description: Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
Study: NCT04481048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eight (8) weeks of treatment with placebo.
Study: NCT00421252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 600 mg
Description: Clopidogrel load \> 2hrs pre-angiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 600 mg
Description: Clopidogrel load \> 2hrs pre-angiography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial access sheath
Description: randomize to 5Fr vs 6Fr

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial access sheath
Description: randomize to 5Fr vs 6Fr
Study: NCT04679467

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU sphere
Description: TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content.
Study: NCT03335358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic (couples-based) positive psychology intervention
Description: Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dyadic (couples-based) positive psychology intervention
Description: Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
Study: NCT03726346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee Full Face Mask
Description: Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
Study: NCT02494791

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire, Educational Material
Description: Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
Study: NCT04307823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: 3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill protocol and Respiratory training
Description: Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks
Study: NCT02428868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid (Exacyl®)
Description: 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid (Exacyl®)
Description: 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous iron (Ferroven®)
Description: 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
Study: NCT02076152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FMISO PET

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FMISO PET

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCNU
Description: A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
Study: NCT02951104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Cardiac Output Monitor (USCOM) system
Study: NCT02882568

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood analysis
Description: Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
Study: NCT01265069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose dual therapy
Description: rabeprazole 20mg qid,amoxicillin 750mg qid for 14days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant therapy
Description: rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
Study: NCT01572727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous paclitaxel 80 mg/m2 per week given until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: intravenous paclitaxel 80 mg/m2 per week given until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BKM120 matching placebo
Description: Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Study: NCT01949480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracoscopic Surgery (VATS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracoscopic Surgery (VATS)
Study: NCT02020954

Intervention type: PROCEDURE
Intervention: ECG, echocardiography, cardiac MRI, sera biomarkers
Study: NCT04556708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: salin irrigation
Description: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozonated water irrigation
Description: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine irrigation
Description: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
Study: NCT04053764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizuamb
Description: Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
Study: NCT03872349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
Study: NCT00402753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory Physical Exercise Program
Description: supervised exercise, 2 x / week
Study: NCT00959517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate (AS)
Description: Recommended dosage over 3 days (for all interventions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate (AS)
Description: Recommended dosage over 3 days (for all interventions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulphadoxine-pyrimethamine (SP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulphadoxine-pyrimethamine (SP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulphadoxine-pyrimethamine (SP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine (PQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine (PQ)
Study: NCT04152733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
Study: NCT01262066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifeskills Workshop Intervention
Description: Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
Study: NCT00232804

Intervention type: DEVICE
Group type: OTHER
Intervention: Bx Cypher stent
Study: NCT01972516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study: NCT01507870

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: onlay mesh placement
Description: prophylactic onlay mesh in patients with median laparotomy
Study: NCT02025777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy